Abstract |
The effects of hexestrol (HXS), medroxyprogesterone acetate (MAP) and chlormadinone acetate (CMA) on 7, 12-dimethylbenz [a] anthracene-induced mammary cancer in rats were evaluated. As a result of successive intramuscular injections of HXS at dosages of 2 or 10 mg/kg or MAP at dosages of 24 or 120 mg/Kg, tumors were markedly reduced in size in all groups on day 7 approximately 14. These effects were the same regardless of the presence or absence of cytoplasmic estrogen receptors (ER) in tumors as determined by the dextran-coated charcoal method. Although such an effect was also seen with CMA, it was much less marked than the effects seen with HXS and MAP. The body weights of HXS-administered groups decreased considerably, whereas those of MAP-administered groups increased. These results may suggest that there is another endocrinological tumor-suppressing mechanism besides the mechanism involving the estrogen-ER system in large-dose administration of HXS and MAP.
|
Authors | T Tominaga, M Kitamura, T Saito, I Itoh |
Journal | Gan
(Gan)
Vol. 72
Issue 4
Pg. 604-9
(Aug 1981)
ISSN: 0016-450X [Print] Japan |
PMID | 6171473
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Delayed-Action Preparations
- Receptors, Estrogen
- Chlormadinone Acetate
- Hexestrol
- 9,10-Dimethyl-1,2-benzanthracene
- Medroxyprogesterone Acetate
- Medroxyprogesterone
|
Topics |
- 9,10-Dimethyl-1,2-benzanthracene
- Animals
- Body Weight
(drug effects)
- Chlormadinone Acetate
(therapeutic use)
- Delayed-Action Preparations
- Female
- Hexestrol
(therapeutic use)
- Mammary Neoplasms, Experimental
(chemically induced, drug therapy, metabolism)
- Medroxyprogesterone
(analogs & derivatives, therapeutic use)
- Medroxyprogesterone Acetate
- Rats
- Rats, Inbred Strains
- Receptors, Estrogen
(metabolism)
|